DR info

臨床試験数 : 30 / 薬物数 : 36 - (DrugBank : 15) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 46

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

ACE I, ATA II and Statins
   Mario Negri Institute for Pharmacological Research
      2004   Phase 2   NCT00309257   Italy;
ACE-inhibitor
   University Hospital Goettingen
      1995   -   NCT02378805   Germany;
AT1-inhibitor
   University Hospital Goettingen
      1995   -   NCT02378805   Germany;
Atrasentan
   Chinook Therapeutics U.S., Inc.
      2021   Phase 2   NCT04573920   Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Bardoxolone methyl
   Reata Pharmaceuticals, Inc
      2018   -   JPRN-UMIN000032448   Japan,North America,Australia,Europe;
   Reata Pharmaceuticals, Inc.
      2019   Phase 3   NCT03749447   Australia;Japan;Puerto Rico;United States;
Benazepril
   Shanghai Children's Hospital
      2020   -   ChiCTR2000036799   China;
Benazepril hydrochloride 10 milligram (mg) Tab
   Shanghai Children's Hospital
      2021   Phase 2   NCT04937907   China;
Benazepril, Valsartan and Fluvastatin
   Mario Negri Institute for Pharmacological Research
      2004   Phase 2   NCT00309257   Italy;
Delix
   University Medical Center Göttingen
      2012   Phase 3   EUCTR2010-024300-10-DE   Germany;
Gold
   Children's Hospital of Shanghai
      2020   Phase 0   ChiCTR2000036550   China;
HMG-Coenzyme inhibitor (statin)
   University Hospital Goettingen
      1995   -   NCT02378805   Germany;
Hydroxychloroquine
   Shanghai Children's Hospital
      2020   -   ChiCTR2000036799   China;
Hydroxychloroquine Sulfate 100 milligram (mg) Tab
   Shanghai Children's Hospital
      2021   Phase 2   NCT04937907   China;
Lademirsen
   Genzyme Corporation
      2020   Phase 2   EUCTR2019-004394-10-DE   Australia;China;France;Germany;Spain;United Kingdom;United States;
Lademirsen (SAR339375)
   Genzyme, a Sanofi Company
      2019   Phase 2   NCT02855268   Australia;Canada;China;France;Germany;Spain;United Kingdom;United States;
Paricalcitol
   University Hospital Goettingen
      1995   -   NCT02378805   Germany;
R3R01
   River 3 Renal Corp.
      2022   Phase 2   NCT05267262   -
RE-021
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   Travere Therapeutics, Inc.
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
RG-012
   Genzyme Corporation
      2020   Phase 2   EUCTR2019-004394-10-DE   Australia;China;France;Germany;Spain;United Kingdom;United States;
   Regulus Therapeutics Inc.
      2016   Phase 2   EUCTR2016-002181-32-GB   Australia;Canada;France;Germany;Spain;United Kingdom;United States;
RG012
   Genzyme, a Sanofi Company
      2017   Phase 1   NCT03373786   United States;
RTA 402
   Reata Pharmaceuticals, Inc.
      2018   Phase 2;Phase 3   EUCTR2016-004395-22-GB   Australia;Canada;France;Germany;Spain;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2016-004395-22-FR   Australia;Canada;France;Germany;Spain;United Kingdom;United States;
      2017   Phase 2;Phase 3   EUCTR2016-004395-22-DE   Australia;Canada;France;Germany;Spain;United Kingdom;United States;
Ramipril
   Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
      2012   Phase 3   NCT01485978   Germany;
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2022   -   NCT05133050   China;
SAR339375
   Genzyme Corporation
      2020   Phase 2   EUCTR2019-004394-10-DE   Australia;China;France;Germany;Spain;United Kingdom;United States;
Sparsentan
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   Travere Therapeutics, Inc.
      2021   Phase 2   NCT05003986   Poland;Spain;United States;
Spironolactone
   University Hospital Goettingen
      1995   -   NCT02378805   Germany;